CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 6 No. 6
 

DDT Appears to Activate Human Estrogen Receptors

June 1, 1997

SAN DIEGO--Reports from the American Association for Cancer Research annual meeting have moved researchers closer to answering the question of whether DDT and its metabolites act as a risk factor for breast cancer by mimicking endogenous estrogen.

Even though DDT was outlawed in the 1970s, the pesticide, which has a half life of 150 years, is still present in the environment and the food chain, and tends to concentrate in the adipose tissue in the breasts and other organs.

A study from the University of Rochester School of Medicine and Dentistry found that DDT compounds could possibly be a more potent risk factor for breast cancer than scientists had previously thought.

Using a recombinant human estrogen receptor in radiolabeled ligand-binding assays, the Rochester scientists found that many DDT metabolites have a significantly higher affinity to human estrogen receptors than to rat estrogen receptors.

"This suggests that humans may be more susceptible to DDT metabolites than other species," said investigator Clarice W. Chen, MS. Both DDT isomers bind to the human estrogen receptor, she pointed out, while only one binds with measurable affinity to the rat estrogen receptor.

At concentrations found in human tissues, DDT compounds and some of their metabolites appear to activate the human estrogen receptor, Ms. Chen said. This potentially could lead to increased expression of estrogen-responsive genes that may be involved in cell proliferation and malignancy.

"Our data suggest the metabolites that activate the human estrogen receptor do so with approximately the same potency as the parent compounds, and this activation is additive to that of another DDT compound or estradiol(Drug information on estradiol)," Ms. Chen said. She urged researchers to focus more attention on the mechanism of action of putative environmental estrogens(Drug information on estrogens).

Role in Breast Cancer Progression

To date, there is no conclusive proof that endogenous estrogens such as estradiol cause breast cancer, said Malathy Shekhar, PhD, of the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit.

The only evidence comes from epidemiologic studies showing an association between an individual's total cumulative exposure to estrogen and breast cancer and from the observation of increased estrogen receptor expression in breast tumors.

In an attempt to provide stronger evidence for this association, Dr. Shekhar and her colleagues examined the effects of estradiol and five closely related organochlorine pesticides, including two DDT isomers, on cell growth in two estrogen-receptor-positive human breast epithelial cell lines.

The cells studied were the preneoplas-tic MCF10AneoT cells and the MCF-7 breast cancer cells.

They found that, administered individually, pesticides caused the human breast epithelial cells to proliferate, but only when given at levels 100- to 1,000-fold higher than estradiol. However, when the two DDT isomers were given in combination, they triggered cell proliferation similar to that detected with physiological concentrations of estradiol.

This led Dr. Shekhar to suggest that some pesticides, especially in combination, may be involved in breast cancer progression.

"We found that in both precancerous and cancerous human breast cell lines, both estradiol and the pesticides activated estrogen-mediated responses via estrogen receptors," she said. "This is an important finding because environmental estrogens such as DDT may still pose a threat to humans even though their use has been banned for many years."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy